Research & Development
Byondis signs License and Collaboration agreement and Supply Agreement with medac GmbH
4 May 2022 -

Byondis BV, an independent, Dutch clinical stage biopharmaceutical company, announced on Tuesday that it has signed a License and Collaboration Agreement and Supply Agreement with medac GmbH, a privately owned pharmaceutical company based in Germany.

Both companies will partner to commercialise Byondis' lead program, anti-HER2 antibody-drug conjugate (ADC) trastuzumab duocarmazine (SYD985), subject to approval by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), and other regulatory authorities in Europe. SYD985 targets a range of HER2-expressing cancers such as metastatic breast and endometrial (uterine) tumours.

According to the terms of the contract, medac will receive an exclusive license to commercialise the product in the EU, the UK and further European countries, in all approved indications. Byondis is to receive an undisclosed upfront payment and sales royalties, and will also be eligible for payments upon achievement of certain development and sales milestones.



Related Headlines